Browsing Tag

#chronickidneydisease

Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of…

Jason Junior Jun 5, 2023

Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete Enrollment by Year End 2023 CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE)…

Health

Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s…

Jason Junior Aug 24, 2022

LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two…

Health

Unicycive Reports Key Findings from Market Research with Nephrologists

Jason Junior Jul 20, 2022

Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. …